Clinical evidence demonstrates that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) effectively decrease urinary albumin excretion rate (UAER) and slow renal function decline, though their nephroprotective benefits prove limited in advanced DN (Liang et al., 2021). This evidence concerns the gene ACE and liver dysplastic nodule.